WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H464227
CAS#: 2750-76-7
Description: Rifamide is an antibiotic derived from Streptomyces mediterranei.
Hodoodo Cat#: H464227
Name: Rifamide
CAS#: 2750-76-7
Chemical Formula: C43H58N2O13
Exact Mass: 810.39
Molecular Weight: 810.938
Elemental Analysis: C, 63.69; H, 7.21; N, 3.45; O, 25.65
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Rifamide; NSC 133099; NSC133099; NSC-133099; Rifamida; Rifamidum; Rifamycin M14;
IUPAC/Chemical Name: N/A
InChi Key: VFYNXKZVOUXHDX-VDPUEHCXSA-N
InChi Code: InChI=1S/C43H58N2O13/c1-12-45(13-2)31(47)20-55-30-19-28-38(51)33-32(30)34-40(26(8)37(33)50)58-43(10,41(34)52)56-18-17-29(54-11)23(5)39(57-27(9)46)25(7)36(49)24(6)35(48)21(3)15-14-16-22(4)42(53)44-28/h14-19,21,23-25,29,35-36,39,48-51H,12-13,20H2,1-11H3,(H,44,53)/b15-14+,18-17+,22-16-/t21-,23+,24+,25+,29-,35-,36+,39+,43-/m0/s1
SMILES Code: CCN(C(COc1c2c(C3=O)c4c(C)c(O)c2c(O)c(NC(/C(C)=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](/C=C/O[C@]3(O4)C)OC)C)OC(C)=O)C)O)C)O)C)=O)c1)=O)CC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: to be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| To be determined | 0.0 | 0.00 |
The following data is based on the product molecular weight 810.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Pahlevan AA, Wright DJ, Bradley L, Smith C, Foxwell BM. Potential of rifamides to inhibit TNF-induced NF-kappaB activation. J Antimicrob Chemother. 2002 Mar;49(3):531-4. doi: 10.1093/jac/49.3.531. PMID: 11864954.
2: Faris MA, Raasch RH, Hopfer RL, Butts JD. Treatment and prophylaxis of disseminated Mycobacterium avium complex in HIV-infected individuals. Ann Pharmacother. 1998 May;32(5):564-73. doi: 10.1345/aph.17275. PMID: 9606478.
3: de Carvalho PS, Mariano RC, Okamoto T. Treatment of fibrinolytic alveolitis with rifamycin B diethylamide associated with gelfoam: a histological study. Braz Dent J. 1997;8(1):3-8. PMID: 9485630.
4: Jones RB, Ridgway GL, Boulding S, Hunley KL. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis. Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S556-61. doi: 10.1093/clinids/5.supplement_3.s556. PMID: 6635445.
5: Keighley MR, Drysdale RB, Quoraishi AH, Burdon DW, Alexander-Willians J. Antibiotics in biliary disease: the relative importance of antibiotic concentrations in the bile and serum. Gut. 1976 Jul;17(7):495-500. doi: 10.1136/gut.17.7.495. PMID: 786807; PMCID: PMC1411162.
6: Reeves DS, Wise R. Letter: Withdrawal of rifamide. Br Med J. 1974 Aug 10;3(5927):414. doi: 10.1136/bmj.3.5927.414. PMID: 4852981; PMCID: PMC1613165.
7: Williams JD. Withdrawal of rifamide. Br Med J. 1974 Jul 6;3(5922):44. doi: 10.1136/bmj.3.5922.44-a. PMID: 4835477; PMCID: PMC1611406.
8: Bevan PG, Williams JD. Rifamide in acute cholecystitis and biliary surgery. Br Med J. 1971 Jul 31;3(5769):284-7. doi: 10.1136/bmj.3.5769.284. PMID: 5557539; PMCID: PMC1799086.
9: Fiorillo AM, da Costa JC. Studies on the effect of rifamide on hepatic function. Arzneimittelforschung. 1971 Mar;21(3):358-60. PMID: 5107971.
10: McGeachie J, Girdwood RW, Burton JA, Kennedy AC. Impaired renal function and serum levels of rifamide. Scott Med J. 1970 Jul;15(7):257-60. doi: 10.1177/003693307001500705. PMID: 5427787.
11: Rifamide (Rifocin-M). Drug Ther Bull. 1968 Oct 25;6(22):86-8. PMID: 5703313.
12: Monnier J, Bourse R. Activité antibactérienne "in vitro" d'une nouvelle rifamycine: la rifamide [Antibacterial activity in vitro of a new rifamycin: rifamide]. Pathol Biol. 1968 Oct;16(19):901-8. French. PMID: 4972879.
13: Resta C, Zema M, Braidotti L. Previsione di stabilità di prodotti farmaceutici. II. Stabilità di una soluione di dietilamide della rifamicina B (Rifamide) [Predicted stability of pharmaceutical products. II. Stability of a solution of rifamycin B diethylamide (Rifamide)]. Farmaco Prat. 1968 Feb;23(2):62-8. Italian. PMID: 5719629.
14: Boccitto G, Sbampato M, Sternini N. Comportamento di alcuni indici biologici di funzionalità epatica e renale in corso di terapia con dietilamide della rifamicina B (rifamide) somministrata per infusione venosa [Behavior of certain biologic parameters of hepatic and renal function during therapy with rifomycin B diethylamide (rifamide) administered by venous infusion]. Ann Ist Carlo Forlanini. 1968;28(2):126-41. Italian. PMID: 5735705.
15: Clark J, Wallace A. The susceptibility of mycobacteria to rifamide and rifampicin. Tubercle. 1967 Jun;48(2):144-8. doi: 10.1016/s0041-3879(67)80009-6. PMID: 4293697.
16: Acocella G, Scalfi U. Ein neues halbsynthetisches Antibiotikum (Rifamid) in der Therapie von Infektionen des Atmungsapparates [A new semi-synthetic antibiotic (Rifamide) in te therapy of infections of the respiratory system]. Wien Med Wochenschr. 1967 Feb 18;117(7):161-4. German. PMID: 5590631.
17: Acocella G, Lamarina F, Tenconi LT, Nicolis FB. Study of the excretion in bile and concentration in the gall bladder wall of rifamide. Gut. 1966 Aug;7(4):380-6. doi: 10.1136/gut.7.4.380. PMID: 5917425; PMCID: PMC1552415.
18: de Barros LC, Hellmeister O, Lima GA. Pneumopatias inespecíficas: pesquisas clínicas e laboratoriais com a rifamida [Non-specific pneumopathies: clinical and laboratory trials of rifamide]. Hospital (Rio J). 1966 Aug;70(2):329-45. Portuguese. PMID: 5300309.
19: Acocella G, Pallanza R, Santilli E, Nicolis FB. Rifamide e rifamicina SV: osservazioni comparative sulla cinetica nell'uomo [Rifamide and rifamycin SV: some comparative observations on kinetics in man]. Antibiotica. 1966 Mar;4(1):17-48. Multiple languages. PMID: 5960847.
20: Dezulian V, Serralunga MG, Maffii G. Pharmacology and toxicology of rifamide. Toxicol Appl Pharmacol. 1966 Jan;8(1):126-37. doi: 10.1016/0041-008x(66)90109-8. PMID: 5950859.
